Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Key Highlights
- ➤MG-ADL reduction 6.6 points at Month 12 after Descartes-08 retreatment
- ➤MGC reduction 15 points at Month 12 after retreatment
- ➤Median retreatment interval reached 16.6 months after initial treatment
- ➤No new safety signals; no serious adverse events during retreatment
- ➤Phase 3 AURORA topline data expected in 1Q27
Expert Statements
James F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine
“Descartes-08 is designed to target BCMA+ immune cells in MG to potentially provide patients with sustained symptom improvement reflected in clinically significant MG-ADL reductions with the added ability to be re-dosed if symptoms recur.”
James F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine
“For patients who have already cycled through multiple therapies, the option to retreat a CAR-T cell therapy, in an outpatient setting and without lymphodepleting chemotherapy, represents an exciting potential advancement in the field of MG.”
Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian
“Descartes-08’s clinical data generated to date has demonstrated the potential for meaningful clinical responses that persist through 12 months following the completion of an initial course of treatment, with the ability to be re-dosed if needed.”
Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian
“These data strengthen our conviction in Descartes-08 as we approach topline results from our Phase 3 AURORA trial, expected in the first quarter of 2027.”
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment
Median interval between end of initial treatment course and first retreatment infusion was 16.6 months
Get started
Create a free account to read the full story.